Trial Profile

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 22 Sep 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NAV 5001 (Primary) ; Ioflupane 123I
Indications Parkinson's disease
Focus Diagnostic use; Registrational
Sponsors Navidea Biopharmaceuticals

Most Recent Events

12 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
29 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2018, according to ClinicalTrials.gov record.
29 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com